Propanc Biopharma, Inc.

Latest News

Nov 17, 2025

Propanc Biopharma Provides Corporate Update and Reports First Quarter 2025/26 Results

MELBOURNE, Australia, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel treatments for recurrent and…

View All Press Releases

Nov 10, 2025

Propanc Biopharma, Inc. Secures up to $100 Million Private Placement to Support Digital Asset Acquisition Strategy & Accelerate Company’s R&D Pipeline

Nov 4, 2025

Propanc Biopharma, Inc. Pursues Strategic Acquisition Plan Targeting Digital Asset Treasury (DAT) Companies Trading Below Market Cap to Net Asset Value (MNAV)

Oct 15, 2025

Propanc Biopharma Announces Strategic Financing Agreement of up to $100 Million with Hexstone Capital
Latest Publication Blocking Tumor Support from Cancer-Associated Fibroblasts in Tumor Microenvironment View All Publications
Trypsinogen and chymotrypsinogen: potent anti- tumor agents
Pancreatic (pro)enzymes treatment suppresses BXPC-3 pancreatic Cancer Stem Cell subpopulation and impairs tumour engrafting
Antitumour efficacy of chymotrypsinogen and trypsinogen